Antidepressant Interactions

Antidepressant Classes Overview

Antidepressants are among the most widely prescribed medications worldwide. Their interaction profiles vary considerably by class, so understanding the different types is a useful starting point:

Class	Examples	Primary Mechanism
SSRIs	Fluoxetine, sertraline, escitalopram, paroxetine, citalopram	Block serotonin reuptake transporter (SERT)
SNRIs	Venlafaxine, duloxetine, desvenlafaxine	Block both serotonin and norepinephrine reuptake
TCAs	Amitriptyline, nortriptyline, imipramine, clomipramine	Block SERT + NET; also block histamine, muscarinic, and alpha receptors
MAOIs	Phenelzine, tranylcypromine, selegiline	Inhibit monoamine oxidase enzyme
Others	Bupropion (NDRI), mirtazapine (NaSSA), trazodone (SARI)	Various mechanisms

Each class carries its own interaction fingerprint.

Serotonin SyndromeSerotonin Syndrome

A potentially life-threatening condition caused by excessive serotonergic activity, usually from combining two or more drugs that increase serotonin levels. Symptoms include agitation, confusion, rapi

: The Most Dangerous Interaction

Serotonin syndrome occurs when the total serotonergic burden on the nervous system exceeds safe levels. Any combination that increases serotonin signaling — whether by blocking its reuptake, inhibiting its breakdown, increasing its synthesis, or directly activating serotonin receptors — can trigger this potentially life-threatening condition.

High-Risk Antidepressant Combinations for Serotonin Syndrome

• Any SSRI or SNRI combined with an MAOI — this is among the most dangerous drug interactions known. A 14-day washout period is required after stopping an SSRI before starting an MAOI (5 weeks for fluoxetine, due to its very long half-lifeHalf-Life

  The time required for the plasma concentration of a drug to decrease by 50%. Half-life determines how often a medication needs to be dosed — drugs with shorter half-lives require more frequent dosing

  and active metabolite). Similarly, 14 days must elapse after stopping an MAOI before starting an SSRI or SNRI.
• SSRIs/SNRIs with tramadol — tramadol inhibits serotonin reuptake in addition to its opioid effects; the combination is a well-documented cause of serotonin syndrome
• SSRIs/SNRIs with triptans — sumatriptan, rizatriptan, and other migraine medications are partial serotonin agonists; combined use has been reported to cause serotonin syndrome, though current evidence suggests the risk is lower than initially feared
• SSRIs/SNRIs with linezolid — this antibiotic is a reversible MAOI; treating infections with linezolid in patients on antidepressants requires careful management
• SSRIs/SNRIs with St. John's Wort — herbal serotonin reuptake inhibitor
• SSRIs/SNRIs with dextromethorphan — cough suppressant found in many OTC products; serotonin syndrome cases have been documented

Recognizing Early Serotonin Syndrome

Early symptoms that should prompt immediate medical evaluation include: - Restlessness, agitation, and anxiety appearing shortly after adding a new medication - Fine muscle twitching (myoclonus) especially in the legs - Diarrhea, sweating, and elevated heart rate together - Temperature rising rapidly

SSRIs as CYP450 Inhibitors

Beyond serotonergic interactions, SSRIs are notable for their inhibition of CYP450 enzymes — and this varies significantly by agent:

SSRI	Primary CYP Inhibition	Clinically Important Interactions
Fluoxetine	CYP2D6 (potent), CYP2C9, CYP3A4	Tricyclics, antipsychotics, tamoxifen, codeine, many others
Paroxetine	CYP2D6 (the most potent SSRI inhibitor)	Same as fluoxetine; risks with tamoxifen particularly well-documented
Fluvoxamine	CYP1A2 (potent), CYP2C9, CYP3A4	Theophylline, clozapine, warfarin, ramelteon
Sertraline	CYP2D6 (moderate at higher doses)	Tricyclics at higher doses
Citalopram/Escitalopram	CYP2D6 (mild)	Fewest CYP interactions among SSRIs

Tamoxifen and CYP2D6 Inhibition

This interaction deserves special attention because of its potential oncological consequences. Tamoxifen is a prodrugProdrug

A pharmacologically inactive compound that is converted to an active drug inside the body through metabolic processes. Prodrugs are designed to improve absorption, reduce side effects, or target drug

converted by CYP2D6 to its most active form, endoxifen. Women with breast cancer who are prescribed tamoxifen and who also take a strong CYP2D6 inhibitor (fluoxetine or paroxetine in particular) may have substantially reduced endoxifen levels, potentially compromising the cancer treatment's effectiveness. Guidelines recommend choosing antidepressants with minimal CYP2D6 inhibition (escitalopram, citalopram, sertraline, venlafaxine) for women on tamoxifen.

MAOI Interactions: The Strictest Rules

MAOIs carry the most extensive interaction list of any antidepressant class. They inhibit monoamine oxidase, the enzyme that degrades serotonin, dopamine, norepinephrine, and tyramine.

Absolute Contraindications

• SSRIs, SNRIs, TCAs, bupropion — serotonin syndrome risk
• Sympathomimetics — decongestants (pseudoephedrine, phenylephrine), stimulant ADHD medications (amphetamines, methylphenidate) can trigger hypertensive crisis
• Meperidine (Demerol) — absolute contraindication; can cause a severe excitatory syndrome
• Buspirone — hypertension risk
• Dextromethorphan — serotonin syndrome risk

The Washout Period Rule

The standard washout period when switching between an MAOI and most other antidepressants is 14 days. The exception is fluoxetine, which requires a 5-week washout before starting an MAOI, due to fluoxetine's exceptionally long half-life (1 to 6 days) and its active metabolite norfluoxetine (half-life of 4 to 16 days).

Missing the washout period — for example, starting an SSRI too soon after stopping an MAOI — has caused deaths from serotonin syndrome.

Antidepressants and Bleeding Risk

SSRIs and SNRIs reduce the amount of serotonin stored in platelets. Platelets normally use serotonin to amplify their aggregation signal — depleting platelet serotonin reduces their ability to form clots. This makes SSRIs mildly antiplatelet in action.

On its own, this effect rarely causes clinically significant bleeding. However, combined with: - NSAIDs (ibuprofen, naproxen, aspirin) — gastrointestinal bleeding risk increases 3-fold or more - Anticoagulants (warfarin, DOACs) — additional bleeding risk - Antiplatelet drugs (clopidogrel, aspirin) — additive antiplatelet effect

Patients who need to take both an SSRI and an NSAID should discuss gastroprotection (a proton pump inhibitor) with their prescriber. The bleeding risk is most concentrated in the gastrointestinal tract.

Tricyclics and QT ProlongationQT Prolongation

A delay in the electrical repolarization of the heart's ventricles, visible on an ECG as a lengthened QT interval. Drug-induced QT prolongation increases the risk of a dangerous heart rhythm called to

Tricyclic antidepressants (TCAs) block cardiac ion channels and prolong the QT interval, predisposing to potentially fatal cardiac arrhythmias. This effect is dose-dependent but becomes relevant at therapeutic doses in vulnerable patients, particularly when other QT-prolonging medications are added.

Drugs That Amplify TCA Cardiac Risk

• Other QT-prolonging drugs (antiarrhythmics, antipsychotics, some antibiotics)
• Drugs that raise TCA blood levels (CYP2D6 inhibitors like fluoxetine or paroxetine, which increase TCA concentrations by blocking their metabolism)
• Anticholinergic drugs (older antihistamines, bladder medications, some antipsychotics) — additive anticholinergic effects: constipation, urinary retention, blurred vision, confusion

TCAs are also profoundly dangerous in overdose — their wide therapeutic-to-toxic ratio is far narrower than SSRIs, and 10 times the daily dose can be fatal in vulnerable individuals. Patients on TCAs should have baseline and periodic ECG monitoring.

Bupropion and Seizure Threshold

Bupropion (Wellbutrin, Zyban) is an antidepressant and smoking cessation aid that lowers the seizure threshold. This is a dose-dependent effect that was responsible for its initial withdrawal from the market in the 1980s, before dose guidelines were revised.

Drugs That Amplify Seizure Risk with Bupropion

• Other drugs that lower the seizure threshold: Tramadol, antipsychotics (particularly clozapine and chlorpromazine), theophylline, systemic corticosteroids (at high doses), and quinolone antibiotics
• Alcohol and sedative withdrawal — seizure risk is elevated during withdrawal from CNS depressants

CYP2D6 Inhibition by Bupropion

Bupropion is also a moderate to strong CYP2D6 inhibitor. This affects: - Codeine and tramadol — reduced conversion to active analgesic forms; reduced pain relief - Metoprolol — blood levels may double, causing pronounced bradycardia and hypotension - Certain antipsychotics and TCAs — elevated levels

Combining Antidepressants

Some clinical situations call for combining antidepressants, particularly for treatment-resistant depression. But not all combinations are safe:

Generally Accepted Combinations

• Mirtazapine + SSRI or SNRI ("California rocket fuel") — well-studied, widely used; mirtazapine adds noradrenergic and histaminergic effects without significant serotonin reuptake inhibition; serotonin syndrome risk is lower than SSRI-SSRI combinations
• Low-dose TCA + SSRI for certain chronic pain or sleep indications — requires monitoring for TCA level elevation due to CYP2D6 inhibition

Combinations to Avoid

• Two serotonin reuptake inhibitors — additive serotonin syndrome risk without clear evidence of benefit
• Any antidepressant + MAOI — as described above, requires strict washout periods
• Bupropion + other seizure-threshold-lowering drugs — at higher doses, seizure risk becomes significant

Switching Antidepressants Safely

Switching from one antidepressant to another requires careful planning to avoid both discontinuation syndrome from the stopped drug and interaction effects during the transition:

Cross-Tapering

Gradually reducing the dose of the first antidepressant while slowly increasing the second — appropriate when switching between most non-MAOI antidepressants.

Direct Switch

Stopping one drug abruptly and starting the next immediately — acceptable with short-acting drugs that have low discontinuation syndrome risk and no interaction risk with the new agent.

Washout Period

Required when either the drug being stopped or the drug being started is an MAOI. The standard rule: 14 days washout after any MAOI, or 14 days before starting any MAOI — extended to 5 weeks when stopping fluoxetine.

When any antidepressant switch is being made, confirm the transition plan with your prescribing clinician and pharmacist, particularly if you are also taking other medications.

Key Takeaways

• Serotonin syndrome is the most serious antidepressant interaction risk — the combination with MAOIs is potentially fatal and requires a 14-day washout period (5 weeks for fluoxetine).
• SSRIs vary in their CYP2D6 inhibition: fluoxetine and paroxetine are the strongest inhibitors; escitalopram is the weakest.
• Women on tamoxifen for breast cancer should avoid strong CYP2D6 inhibitors — choose antidepressants with minimal inhibition.
• SSRIs combined with NSAIDs triple the risk of gastrointestinal bleeding; gastroprotection should be considered.
• Tricyclics prolong the QT interval — risk is amplified by other QT-prolonging drugs or drugs that raise TCA blood levels.
• Bupropion lowers the seizure threshold and inhibits CYP2D6 — relevant for codeine, metoprolol, and other CYP2D6 substrates.
• MAOI washout periods must be strictly observed — missing them has caused deaths.